Page 23 - 《中国药房》2021年2期

10.3402/jmahp.v4.30970. chemotherapy[EB/OL].（2018-05-16）[2020-12-06]. https：//
[19] GRANDFILS N. Working paper：drug price setting and www.nice.org.uk/guidance/ta520.
regulation in France[EB/OL].（2008-09）[2020-12-17]. [32] National Institute for Health and Care Excellence. Tech-
https：//www.irdes.fr/EspaceAnglais/Publications/Work- nology appraisal guidance：atezolizumab for treating locally
ingPapers/DT16DrugPriceSettingRegulationFrance.pdf. advanced or metastatic urothelial carcinoma after plati-
[20] TOUMI M，MORTRUNICH A，MILLIER A，et al. Analy- num-containing chemotherapy[EB/OL].（2018-06-13）[2020-
sis of health economics assessment reports for pharmaceu- 12-06]. https：//www.nice.org.uk/guidance/ta525.
ticals in France：understanding the underlying philosophy [33] National Institute for Health and Care Excellence. Tech-
of CEESP assessment[J]. J Mark Access Health Policy， nology appraisal guidance：atezolizumab in combination
2017. DOI：10.1080/20016689.2017.1344088. for treating metastatic non-squamous non-small-cell lung
[21] WENZL M，PARIS V. Pharmaceutical reimbursement and cancer[EB/OL].（2019-06-05）[2020-12-06]. https：//www.
pricing in Germany[EB/OL]. （2018-06） [2020-09-20]. nice.org.uk/guidance/ta584.
https：//www.oecd.org/health/health-systems/Pharmaceuti- [34] National Institute for Health and Care Excellence. Tech-
cal-Reimbursement-and-Pricing-in-Germany.pdf. nology appraisal guidance：atezolizumab with nabpaclitax-
[22] 常峰，崔鹏磊，夏强，等.德国药品参考价格体系对构建我 el for untreated PDL1-positive，locally advanced or meta-
国医保支付标准的启示[J].中国卫生政策研究，2015，8
static，triple-negative breast cancer[EB/OL].（2020-07-01）
（7）：55-60.
[2020-12-06]. https：//www.nice.org.uk/guidance/ta639.
[23] NERI M，TOWSE A，GARAU M. Multi-indication pricing [35] National Institute for Health and Care Excellence. Tech-
（MIP）：practical solutions and steps to move forward[R].
nology appraisal guidance：atezolizumab with carboplatin
London：Office of Health Economics，2018.
and etoposide for untreated extensive-stage small-cell
[24] LAUENROTH VD，STARGARDT T. Pharmaceutical pric-
lung cancer[EB/OL].（2020-07-01）[2020-12-06]. https：//
ing in Germany：how is value determined within the scope
www.nice.org.uk/guidance/ta638.
of AMNOG? [J]. Value Health，2017，20（7）：927-935.
[36] JOMMI C，MINHRTTI P. Pharmaceutical pricing policies
[25] Department of Health & Social Care. Pharmaceutical price
in Italy[M].Cham：Adis，2015：131-150.
regulation scheme 2014[EB/OL].（2013-12-03）[2020-09-
[37] NAVARRIA A，DRAGO V，GOZZO L，et al. Do the cur-
20]. https：//www.gov.uk/government/publications/pharma-
ceutical-price-regulation-scheme-2014. rent performance-based schemes in Italy really work：
“Success fee”：a novel measure for cost-containment of
[26] Department of Health & Social Care. The 2019 voluntary
drug expenditure[J]. Value Health，2015，18（1）：131-136.
scheme for branded medicines pricing and access[EB/OL].
[38] SVENSSON M，NILSSON FOL，ARNBERG K. Reim-
（2018-12-05）[2020-12-06]. https：//assets.publishing.ser-
bursement decisions for pharmaceuticals in Sweden：the
vice.gov.uk/government/uploads/system/uploads/attach-
ment_data/file/761834/voluntary-scheme-for-brandedmedi- impact of disease severity and cost effectiveness[J]. Phar-
cines-pricing-and-access-chapters-and-glossary.pdf. macoeconomics，2015，33（11）：1229-1236.
[27] TOWSE A，COLE A，ZAMORA B. The debate on indica- [39] PERSSON U，NORLIN JM. Multi-indication and combi-
tion-based pricing in the US and five major European nation pricing and reimbursement of pharmaceuticals：op-
countries[R]. London：Office of Health Economics，2018. portunities for improved health care through faster uptake
[28] PANTELI D，ARICKX F，CLEEMPUT I，et al. Pharma- of new innovations[J]. Appl Health Econ Health Policy，
ceutical regulation in 15 European countries review[J]. 2018，16（2）：157-165.
Health Syst Transit，2016，18（5）：1-122. [40] Tandvårds-och Läkemedelsförmåns Verket. PPRI phar-
[29] LEELA B. Patient access schemes：a look behind the ma profile Sweden 2017[EB/OL].（2017-04）[2020-12-22].
scenes[EB/OL].（2015）[2020-09-20]. https：//pharmapho- https：//www.tlv.se/download/18.1d85645215ec7de284611-
rum.com/views-and-analysis/patient-accessschemes-a-look- ebd/1510316381520/ppri_pharma_profile_sweden_2017.
behind-the-scenes/. pdf.
[30] National Institute for Health and Care Excellence. Tech- [41] MESRRE-FERRANDIZ J，TOWSE A，DELLAMANO R，
nology appraisal guidance：atezolizumab for untreated et al. Multi-indication pricing：pros，cons and applicability
PDL1-positive locally advanced or metastaticurothelial to the UK[R]. London：Office of Health Economics，2015.
cancer when cisplatin is unsuitable[EB/OL].（2017-12-06） [42] GARTTINI L，CURTO A，VANDEVOORENK. Italian risk-
[2020-12-06]. https：//www.nice.org.uk/guidance/ta492. sharing agreements on drugs：are they worthwhile?[J].Eur
[31] National Institute for Health and Care Excellence. Tech- J Health Econ，2015，16（1）：1-3.
nology appraisal guidance：atezolizumab for treating local- （收稿日期：2020-10-27 修回日期：2020-12-18）
ly advanced or metastatic non-small-cell lung cancer after （编辑：孙 冰）

中国药房 2021年第32卷第2期 China Pharmacy 2021 Vol. 32 No. 2 ·145 ·